Signadori Bio is a preclinical-stage biopharmaceutical company developing an innovative cell therapy platform to transform cancer treatment. The company’s proprietary platform originates from Institut Gustave Roussy, a globally renowned oncology center.
- CEO: Selwyn Ho
- Scientific Founders: Dr. Jean-Luc Perfettini and Professor Nathalie Chaput
- Location: France
- Website: signadoribio.com